The latest from
Blue River Bio
- Recognition
Blue River Bio selected as a finalist for Start-Up Stadium at BIO 2026
Blue River Bio was one of roughly 40 early-stage companies chosen to pitch to investors and judges at the BIO International Convention in San Diego.
Read more
- Program
HIT Fund renews its support for Blue River Bio
The High Impact Technology Fund renewed its support for Blue River Bio's program in June 2026, awarding funding to advance the work it has backed since the company's earliest days.
Read more - Award
First place at the Stanford GSB Healthcare Innovation Summit pitch competition
Blue River Bio won the pitch competition at Stanford's premier healthcare and life sciences event, earning nearly twice the votes of any other team.
Read more - Award
Blue River Bio's founding team receives the Stanford SPARK Award for Excellence
The SPARK Translational Research Program honored the team led by Patrick Purdon as the single project, among more than 50, showing outstanding progress toward the clinic.
Read more - Program
Blue River Bio joins the StartX Summer 2025 founder cohort
We were one of a small number of teams selected for StartX, the premier community for Stanford founders, which takes no equity and charges no fees.
Read more - Program
High Impact Technology Fund selects Blue River Bio's program
The High Impact Technology (HIT) Fund selected Blue River Bio's program for a competitive award that pairs teams with executive advisors and industry connections to de-risk commercialization.
Read more - Program
Awarded a Stanford-Coulter Translational Research Grant
The competitive Coulter grant supports multidisciplinary Stanford teams developing technologies that address unmet clinical needs and lead to commercial products.
Read more - Program
Accepted into the Stanford SPARK Translational Research Program
Our acute pain program was one of 18 teams selected for SPARK, Stanford's flagship program for advancing academic discoveries from laboratory to patient care.
Read more
